Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK.
Future Microbiol
; 13: 1283-1293, 2018 09.
Article
em En
| MEDLINE
| ID: mdl-29911889
ABSTRACT
AIM:
Invasive mold diseases (IMDs) are associated with significant morbidity and mortality. Approved treatments include voriconazole (VORI), liposomal amphotericin B (L-AMB), posaconazole (POSA) and isavuconazole (ISAV). A UK-based economic model was developed to explore the cost of treating IMDs with ISAV versus L-AMB followed by POSA. MATERIALS &METHODS:
As indirect comparisons have demonstrated similar efficacy between the comparators, a cost-minimization approach was taken. Drug acquisition, administration & monitoring, and hospitalization costs were evaluated from the healthcare system perspective.RESULTS:
Per-patient costs were UK£14,842 with ISAV versus UK£18,612 with L-AMB followed by POSA. Savings were driven by drug acquisition, and administration & monitoring costs.CONCLUSION:
ISAV has the potential to reduce IMD treatment costs relative to L-AMB followed by POSA.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piridinas
/
Aspergilose
/
Triazóis
/
Anfotericina B
/
Custos de Cuidados de Saúde
/
Mucormicose
/
Antifúngicos
/
Nitrilas
Tipo de estudo:
Health_economic_evaluation
Limite:
Humans
País/Região como assunto:
Europa
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article